Antitumor immunotherapeutic effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice

树突状细胞与肝癌细胞融合免疫小鼠的抗肿瘤免疫治疗作用

• 批准号: 14570443
• 负责人: SATO Koji
• 金额: $ 1.86万
• 依托单位: Yamagata University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570443/
• 关键词: Hepatocellular carcinoma; Pervention; Cancer vaccine; Dendritic cell; Immunotherapy; 肝細胞癌; 癌ワクチン療法

The long-term prognosis after treatment of hepatocellular carcinoma (HCC) remains poor because of high rate of tumor recurrence. Immunotherapy for cancer is attractive. Uncharacterized and mutated antigens can be targeted with whole tumor cell or tumor lysate-based immunization strategies.Our study was to investigate the antitumor effects of immunization with fusions of dendritic cells (DCs) and HCC cells against HCC tumors transplanted to mice.Fusion cells of DCs and tumor cells were prepaired with polyethylene glycol. To study the antitumor immune effects, fusions were subcutaneously injected into mice. The CTL activity was assumed by the LDH method. Mice were followed for survival and tumor size.Immunization of mice with fusions induced protective immunity against tumor challenge. Tumor antigen-pulsed DCs effectively suppressed the growth of HCC in mice. After treatment with fusions, tumor size decreased and the survival time of tumor-bearing mice was extended.Our study demonstrated that the fusion cells of DCs and tumor cells could induce effective antitumor immune responses and may be used in HCC treatment and prevention of recurrence of HCC.

肝细胞癌（HCC）治疗后的长期预后仍然很差，因为肿瘤复发率很高。癌症的免疫疗法很有吸引力。未表征的和突变的抗原可以用全肿瘤细胞或肿瘤裂解物为基础的免疫策略靶向。本研究旨在探讨树突状细胞（dc）与肝癌细胞融合免疫对移植小鼠肝癌肿瘤的抗肿瘤作用。用聚乙二醇制备树突状细胞与肿瘤细胞融合细胞。为了研究其抗肿瘤免疫作用，将融合物皮下注射到小鼠体内。CTL活性由LDH法测定。观察小鼠的存活率和肿瘤大小。小鼠融合免疫诱导抗肿瘤的保护性免疫。肿瘤抗原脉冲dc有效抑制小鼠肝细胞癌的生长。经融合治疗后，肿瘤体积减小，荷瘤小鼠存活时间延长。我们的研究表明，树突状细胞与肿瘤细胞的融合细胞可以诱导有效的抗肿瘤免疫反应，可能用于HCC的治疗和预防HCC的复发。